Adaptations in adenosine signaling in drug dependence: Therapeutic implications

Critical Reviews in Neurobiology

Volumn 15, Issue 3-4, 2003, Pages 235-274

  Hack, Stephen P ^a,b   Christie, Macdonald J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Adenine nucleotides; Adenosine; Alcohol; Caffeine; Cannabinoids; Cocaine; Cyclic AMP; Drug addiction; Nociception; Opioids

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 2 AMINO 6 BENZYL 3 (4 CHLOROBENZOYL) 4,5,6,7 TETRAHYDROTHIENO[2,3 C]PYRIDINE; 2 CHLORO 6 N CYCLOPENTYLADENOSINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENYLATE CYCLASE; ALCOHOL; ATL 525; CANNABINOID; COCAINE; CYCLIC AMP; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; ION CHANNEL; ISOBUTYLMETHYLXANTHINE; MORPHINE; MRS 1706; NUCLEOSIDE TRANSPORTER; OPIATE; T 62; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALCOHOL CONSUMPTION; CENTRAL NERVOUS SYSTEM; COCAINE DEPENDENCE; DESENSITIZATION; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; EPILEPSY; HUMAN; NONHUMAN; PAIN; RAT; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; SLEEP DISORDER;

ADENOSINE; ANIMALS; BRAIN CHEMISTRY; HUMANS; SIGNAL TRANSDUCTION; SUBSTANCE-RELATED DISORDERS;

EID: 3142744648     PISSN: 08920915     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevNeurobiol.v15.i34.30     Document Type: Review

References (307)

1. Harwood HJ, Fountain D, Livermore G. Cost estimates for alcohol and drug abuse. Addiction 1999; 94(5):631-647.
2. Pouletty P. Drug addictions: towards socially accepted and medically treatable diseases. Nat Rev Drug Discov 2002; 1(9):731-736.
3. Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions. Nat Rev Drug Discov 2002; 1(9): 710-726.
4. Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron 1998; 21:467-476.
5. Koob GF. Neurobiology of addiction: toward the development of new therapies. Ann NY Acad Sci 2000; 909(1):170-185.
6. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997; 278(5335): 52-8.
7. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2000; 24(2):97-129.
8. Leshner AI. Addiction is a brain disease, and it matters. Science 1997; 278(5335):45-47.
9. Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nature Rev Neurosci 2001; 2: 119-128.
10. Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science 1997; 278(5335):58-63.
11. Cami J, Farre M. Drug addiction. N Engl J Med 2003; 349(10):975-986.
12. Chao J, Nestler EJ. Molecular neurobiology of drug addiction. Annu Rev Med 2004; 55(1):113-132.
13. Sawynok J, Liu X-J. Adenosine in the spinal cord and periphery: release and regulation of pain. Progr Neurobiol 2003; 69:313-340.
14. Abbracchio MP, Cattabeni F. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases. Ann NY Acad Sci 1999; 890(1):79-92.
15. Poulsen S-A, Quinn RJ. Adenosine receptors: new oppoutunities for future drugs. Bioorg Medic Chem 1998; 6:619-641.
16. 3H xanthine amine congener) ligand probe. Neurosci Lett 1988; 86(2):121-126.
17. 1 receptors in the human brain: a quantitative autoradiographic study. Neuroscience 1987; 22(3): 827-839.
18. 125I-HPIA. Neurosci Lett 1988; 87(3):215-220.
19. 1 receptors. Brain Res 1996; 710(1-2):79-91.
20. 1 receptors and 5′-nucleotidase in the brain and of some commonly used experimental animals. Neuroscience 1987; 22(3):813-826.
21. Lee KS, Reddington M. Autoradiographic evidence for multiple CNS binding sites for adenosine derivatives. Neuroscience 1986; 19(2):535-549.
22. Ribeiro JA, Sebastiao AM, de Mendonca A. Adenosine receptors in the nervous system: pathophysiological implications. Progr Neurobiol 2003; 68: 377-392.
23. Dunwiddie TV, Diao L. Extracellular adenosine concentrations in hippocampal brain slices and the tonic inhibitory modulation of evoked excitatory responses. J Pharmacol Exp Ther 1994; 268(2):537-545.
24. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999; 51(1):83-133.
25. Latini S, Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 2001; 79(3):463-484.
26. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001; 24(1):31-55.
27. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev 1994; 46(2):143-156.
28. Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53(4):527-552.
29. Haas HL, Selbach O. Functions of neuronal adenosine receptors. Naunyn Schmiedeberg's Arch Pharmacol 2000; 362:375-381.
30. Fredholm BB, Dunwiddie TV. How does adenosine inhibit transmitter release? Trends Pharmacol Sci 1988; 9(4):130-134.
31. 1 adenosine receptors expressed in CHO-cells couple to adenylyl cyclase and to phospholipase C. Naunyn Schmiedebergs Arch Pharmacol 1994; 350(1):49-56.
32. 1 adenosine receptor expressed in Chinese hamster ovary cells not only inhibits cAMP accumulation but also stimulates phospholipase C and arachidonate release. Mol Pharmacol 1994; 45(5):1036-1042.
33. 1 receptor-activated potassium current in rat locus ceruleus neurons. J Pharmacol Exp Ther 1995; 273(1):537-544.
34. Mager R, Ferroni S, Schubert P. Adenosine modulates a voltage-dependent chloride conductance in cultured hippocampal neurons. Brain Res 1990; 532(1-2):58-62.
35. Dolphin AC, Forda SR, Scott RH. Calcium-dependent currents in cultured rat dorsal root ganglion neurones are inhibited by an adenosine analogue. J Physiol 1986; 373:47-61.
36. Ribeiro JA. Purinergic inhibition of neurotransmitter release in the central nervous system. Pharmacol Toxicol 1995; 77(5):299-305.
37. Yoon KW, Rothman SM. Adenosine inhibits excitatory but not inhibitory synaptic transmission in the hippocampus. J Neurosci 1991; 11(5):1375-1380.
38. Scanziani M, Capogna M, Gahwiler BH, Thompson SM. Presynaptic inhibition of miniature excitatory synaptic currents by baclofen and adenosine in the hippocampus. Neuron 1992; 9(5):919-927.
39. Scholz KP, Miller RJ. Inhibition of quantal transmitter release in the absence of calcium influx by a G protein-linked adenosine receptor at hippocampal synapses. Neuron 1992; 8(6):1139-1150.
40. Wu LG, Saggau P. Adenosine inhibits evoked synaptic transmission primarily by reducing presynaptic calcium influx in area CA1 of hippocampus. Neuron 1994; 12(5):1139-1148.
41. Uchimura N, North RA. Baclofen and adenosine inhibit synaptic potentials mediated by gamma-aminobutyric acid and glutamate release in rat nucleus accumbens. J Pharmacol Exp Ther 1991; 258(2): 663-668.
42. Brundege JM, Williams JT. Differential modulation of nucleus accumbens synapses. J Neurophysiol 2002; 88(1):142-151.
43. Heinbockel T, Pape H-C. Modulatory effects of adenosine on inhibitory postsynaptic potentials in the lateral amygdala of the rat. Br J Pharmacol 1999; 128(1):190-196.
44. 1 receptors regulate synaptic transmission to rat substantia nigra reticulata neurones. J Physiol (Lond) 1997; 505(1):153-163.
45. Bagley EE, Vaughan CW, Christie MJ. Inhibition by adenosine receptor agonists of synaptic transmission in rat periaqueductal grey neurons. J Physiol 1999; 516(Pt 1):219-225.
46. Brundege JM, Dunwiddie TV. Modulation of excitatory synaptic transmission by adenosine released from single hippocampal pyramidal neurons. J Neurosci 1996; 16(18):5603-5612.
47. Manzoni O, Pujalte D, Williams J, Bockaert J. Decreased presynaptic sensitivity to adenosine after cocaine withdrawal. J Neurosci 1998; 18(19):7996-8002.
48. 1 receptor mediated depression of corticostriatal and thalamostriatal glutamatergic synaptic potentials in vitro. Brain Res 1997; 778:178-185.
49. Hugel S, Schlichter R. Convergent control of synaptic GABA release from rat dorsal horn neurones by adenosine and GABA autoreceptors. J Physiol (Lond) 2003; 551(2):479-489.
50. Fiorillo CD, Williams JT. Selective inhibition by adenosine of mGluR IPSPs in dopamine neurons after cocaine treatment. J Neurophysiol 2000; 83(3): 1307-1314.
51. Hack SP, Vaughan CW, Christie MJ. Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro. Neuropharmacology 2003; 45(5):575-584.
52. Bonci A, Williams JT. Increased probability of GABA release during withdrawal from morphine. J Neurosci 1997; 17(2):796-803.
53. 2A receptors: an overview. Brain Rese Rev 1999; 31:65-82.
54. Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 1996; 118(6):1461-1468.
55. 2A receptors in the rat central nervous system. J Compar Neurol 1998; 401:163-186.
56. 2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 1992; 14(3):186-195.
57. 2A receptor mRNA in the primate striatum. J Comp Neurol 1998; 399(2):229-240.
58. olf Levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J Neurosci 2001; 21(12):4390-4399.
59. olf in rat striatum. Mol Pharmacol 2000; 58(4):771-777.
60. 2A receptor involves activation of both N- and P-type calcium channels by different G proteins and protein kinases in the same striatal nerve terminals. J Neurochem 1996; 67(1):374-381.
61. 2A receptor facilitation of synaptic transmission in the CA1 area of the rat hippocampus requires protein kinase C but not protein kinase A activation. Neurosci Lett 2000; 289:127-1130.
62. A-mediated IPSCs in the rat globus pallidus. J Physiol (Lond) 2001; 532(2):423-434.
63. 2A receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus. Br J Pharmacol 2002; 136(2):296-302.
64. Norenberg W, Wirkner K, Illes P. Effect of adenosine and some of its structural analogues on the conductance of NMDA receptor channels in a subset of rat neostriatal neurones. Br J Pharmacol 1997; 122(1):71-80.
65. 2A receptors of NMDA but not AMPA currents in rat neostriatal neurons. Br J Pharmacol 2000; 130(2):259-269.
66. 2A receptors modulate hippocampal synaptic transmission via a cylic-AMP-dependent pathway. Neuroscience 1998; 84(1):59-69.
67. 2 receptor-mediated postsynaptic AMPA potentiation in hippocampus. J Neurophysiol 1997; 78(4):1965-1972.
68. Klotz KN. Adenosine receptors and their ligands. Naunyn Schmiedeberg's Arch Pharmacol 2000; 362: 382-391.
69. 1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists. Br J Pharmacol 1997; 122(6):1202-1208.
70. Olah M, Stiles G. The role of receptor structure in determining adenosine receptor activity. Pharmacol Therapeut 2000; 85:55-75.
71. 1-adenosine receptor. J Biol Chem 1994; 269(51): 32077-32084.
72. 2A receptors. Biochem Pharmacol 1999; 57:65-67.
73. Neubig RR, Spedding M, Kenakin T, Christopoulos A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 2003; 55(4):597-606.
74. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 2002; 1(3):198-210.
75. Christopoulos A, Kenakin T. G Protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002; 54(2):323-374.
76. 1 adenosine receptors increase receptor-G protein coupling and counteract guanine nucleotide effects on agonist binding. Mol Pharmacol 2003; 64(6):1557-1564.
77. May LT, Christopoulos A. Allosteric modulators of G-protein-coupled receptors. Curr Opin Pharmacol 2003; 3:551-556.
78. Cunha RA, Brendel P, Zimmermann H, Ribeiro JA. Immunologically distinct isoforms of ecto-5′-nucleotidase in nerve terminals of different areas of the rat hippocampus. J Neurochem 2000; 74(1):334-338.
79. 1 receptors. J Neurosci 1998; 18(6): 1987-1995.
80. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedeberg's Arch Pharmacol 2000; 362:299-309.
81. Dunwiddie TV, Diao L, Proctor WR. Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracellular space in rat hippocampus. J Neurosci 1997; 17(20):7673-7682.
82. Rosenberg PA, Knowles R, Knowles KP, Li Y. β-adrenergic receptor-mediated regulation of extracellular adenosine in cerebral cortex in culture. J Neurosci 1994; 14(5 Pt 2):2953-2965.
83. Rosenberg PA, Li Y. Adenylyl cydase activation underlies intracellular cyclic AMP accumulation, cyclic AMP transport, and extracellular adenosine accumulation evoked by β-adrenergic receptor stimulation in mixed cultures of neurons and astrocytes derived from rat cerebral cortex. Brain Res 1995; 692(1-2):227-232.
84. Rosenberg PA, Li Y. Forskolin evokes extracellular adenosine accumulation in rat cortical cultures. Neurosci Lett 1996; 211(1):49-52.
85. Brundege JM, Diao L, Proctor WR, Dunwiddie TV. The role of cyclic AMP as a precursor of extracellular adenosine in the rat hippocampus. Neuropharmacology 1997; 36(9):1201-1210.
86. Gereau RW, Conn PJ. Potentiation of CAMP responses by metabotropic glutamate receptors depresses excitatory synaptic transmission by a kinase-independent mechanism. Neuron 1994; 12(5):1121-1129.
87. Bonci A, Williams JT. A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine. Neuron 1996; 16(3):631-639.
88. Craig CG, Temple SD, White TD. Is cyclic AMP involved in excitatory amino acid-evoked adenosine release from rat cortical slices? Eur J Pharmacol 1994; 269(1):79-85.
89. Cass CE, Young JD, Baldwin SA. Recent advances in the molecular biology of nucleoside transporters of mammalian cells. Biochem Cell Biol 1998; 76(5): 761-770.
90. Thorn JA, Jarvis SM. Adenosine transporters. Gen Pharmacol 1996; 27(4):613-620.
91. Anderson CM, Baldwin SA, Young JD, Cass CE, Parkinson FE. Distribution of mRNA encoding a nitrobenzylthioinosine-insensitive nucleoside transporter (ENT2) in rat brain. Brain Res Mol Brain Res 1999; 70(2):293-297.
92. Anderson CM, Xiong W, Geiger JD, Young JD, Cass CE, Baldwin SA, et al. Distribution of equilibrative, nitrobenzylthioinosine-sensitive nucleoside transporters (ENT1) in brain. J Neurochem 1999; 73(2): 867-873.
93. Snell BJ, Short JL, Drago J, Ledent C, Lawrence AJ. Characterization of central adenosine A(1) receptors and adenosine transporters in mice lacking the adenosine A(2a) receptor. Brain Res 2000; 877(2): 160-169.
94. Brundege JM, Dunwiddie TV. Metabolic regulation of endogenous adenosine release from single neurons. Neuroreport 1998; 9(13):3007-3011.
95. Nagy JI, Yamamoto T, Dewar K, Geiger JD, Daddona PE. Adenosine deaminase-'like' immunoreactivity in cerebellar Purkinje cells of rat. Brain Res 1988; 457(1):21-28.
96. Nagy JI, Yamamoto T, Uemura H, Schrader WP. Adenosine deaminase in rodent median eminence: detection by antibody to the mouse enzyme and colocalization with adenosine deaminase-complexing protein (CD26). Neuroscience 1996; 73(2):459-471.
97. Senba E, Daddona PE, Nagy JI. Adenosine deaminase-containing neurons in the olfactory system of the rat during development. Brain Res Bull 1987; 18(5):635-648.
98. Senba E, Daddona PE, Nagy JI. A subpopulation of preganglionic parasympathetic neurons in the rat contain adenosine deaminase. Neuroscience 1987; 20(2):487-502.
99. Staines WA, Daddona PE, Nagy JI. The organization and hypothalamic projections of the tuberomammillary nucleus in the rat: an immunohistochemical study of adenosine deaminase-positive neurons and fibers. Neuroscience 1987; 23(2): 571-596.
100. Staines WA, Yamamoto T, Dewar KM, Daddona PE, Geiger JD, Nagy JI. Distribution, morphology and habenular projections of adenosine deaminase-containing neurons in the septal area of rat. Brain Res 1988; 455(1):72-87.
101. Yamamoto T, Geiger JD, Daddona PE, Nagy JI. Subcellular, regional and immunohistochemical localization of adenosine deaminase in various species. Brain Res Bull 1987; 19(4):473-484.
102. Yamamoto T, Ochi J, Daddona PE, Nagy JI. Ultrastructural immunolocalization of adenosine deaminase in histaminergic neurons of the tuberomammillary nucleus of rat. Brain Res 1990; 527(2): 335-341.
103. Yamamoto T, Shiosaka S, Daddona PE, Nagy JI. Further observations on the relationship between adenosine deaminase-containing axons and trigeminal mesencephalic neurons: an electron microscopic, immunohistochemical and anterograde tracing study. Neuroscience 1988; 26(2):669-680.
104. Yamamoto T, Staines WA, Dewar K, Geiger JD, Daddona PE, Nagy JI. Distinct adenosine deaminase-containing inputs to the substantia nigra from the striatum and tuberomammillary nucleus. Brain Res 1988; 474(1):112-124.
105. Franco R, Casado V, Ciruela F, Saura C, Mallol J, Canela EI, et al. Cell surface adenosine deaminase: much more than an ectoenzyme. Prog Neurobiol 1997; 52(4):283-294.
106. Pak MA, Haas HL, Decking UK, Schrader J. Inhibition of adenosine kinase increases endogenous adenosine and depresses neuronal activity in hippocampal slices. Neuropharmacology 1994; 33(9):1049-1053.
107. Geiger JD, Parkinson FE, Kowaluk EA. Regulators of endogenous adenosine levels as therapeutic agents. In: Jacobson KA, Jarvis MF, editors. Purinergic Approaches in Experimental Therapeutics. New York: Wiley-Liss, 1997.
108. Delaney SM, Geiger JD. Levels of endogenous adenosine in rat striatum. II. Regulation of basal and N-methyl-D-aspartate-induced levels by inhibitors of adenosine transport and metabolism. J Pharmacol Exp Ther 1998; 285(2):568-572.
109. Lloyd HG, Fredholm BB. Involvement of adenosine deaminase and adenosine kinase in regulating extracellular adenosine concentration in rat hippocampal slices. Neurochem Int 1995; 26(4):387-395.
110. Reddington M, Pusch R. Adenosine metabolism in a rat hippocampal slice preparation: incorporation into S-adenosylhomocysteine. J Neurochem 1983; 40(1):285-290.
111. Schug SA, Zech D, Grond S. Adverse effects of systemic opioid analgesics. Drug Safety 1992; 7(3): 200-213.
112. Breivik H. Opioids in cancer and chronic non-cancer pain therapy-indications and controversies. Acta Anaesthesiol Scand 2001; 45(9):1059-1066.
113. Stein C, Schafer M, Machelska H. Why is morphine not the ultimate analgesic and what can be done to improve it? J Pain 2000; 1(Suppl 3):51-56.
114. Connor M, Christie MJ. Opioid receptor signaling mechanisms. Clin Exp Pharmacol Physiol 1999; 26(7):493-499.
115. Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 2000; 40:389-430.
116. Vaughan CW, Ingram SL, Connor MA, Christie MJ. How opioids inhibit GABA-mediated neurotransmission. Nature 1997; 390(6660):611-614.
117. Sharma SK, Klee WA, Nirenberg M. Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad Sci USA 1975; 72(8):3092-3096.
118. Capogna M, Gahwiler BH, Thompson SM. Presynaptic enhancement of inhibitory synaptic transmission by protein kinases A and C in the rat hippocampus in vitro. J Neurosci 1995; 15(2):1249-1260.
119. Sciancalepore M, Cherubini E. Protein kinase A-dependent increase in frequency of miniature GABAergic currents in rat CA3 hippocampal neurons. Neurosci Lett 1995; 187(2):91-94.
120. Chavez-Noriega LE, Stevens CF. Increased transmitter release at excitatory synapses produced by direct activation of adenylate cyclase in rat hippocampal slices. J Neurosci 1994; 14(1):310-317.
121. Chen C, Regehr WG. The mechanism of cAMP-mediated enhancement at a cerebellar synapse. J Neurosci 1997; 17(22):8687-8694.
122. Wang LY, Salter MW, MacDonald JF. Regulation of kainate receptors by cAMP-dependent protein kinase and phosphatases. Science 1991; 253(5024): 1132-1135.
123. Ingram SL, Vaughan CW, Bagley EE, Connor M, Christie MJ. Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway. J Neurosci 1998; 18(24):10269-10276.
124. Chieng B, Williams JT. Increased opioid inhibition of GABA release in nucleus accumbens during morphine withdrawal. J Neurosci 1998; 18(17):7033-7039.
125. Shoji Y, Delfs J, Williams JT. Presynaptic inhibition of GABAB-mediated synaptic potentials in the ventral tegmental area during morphine withdrawal. J Neurosci 1999; 19(6):2347-2355.
126. Williams JT, Christie MJ, Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 2001; 81(1):299-343.
127. Ho IK, Loh HH, Way EL. Cyclic adenosine monophosphate antagonism of morphine analgesia. J Pharmacol Exp Ther 1973; 185(2):336-346.
128. Ahlijanian MK, Takemori AE. Effects of (-)-N6-(R-phenylisopropyl)- adenosine (PIA) and caffeine on nociception and morphine-induced analgesia, tolerance and dependence in mice. Eur J Pharmacol 1985; 112(2):171-179.
129. Contreras E, Germany A, Villar M. Effects of some adenosine analogs on morphine-induced analgesia and tolerance. Gen Pharmacol 1990; 21(5):763-767.
130. DeLander GE, Hopkins CJ. Spinal adenosine modulates descending antinociceptive pathways stimulated by morphine. J Pharmacol Exp Ther 1986; 239(1):88-93.
131. Sawynok J, Espey MJ, Reid A. 8-Phenyltheophylline reverses the antinociceptive action of morphine in the periaqueductal gray. Neuropharmacology 1991; 30(8):871-877.
132. Butt NM, Collier HO, Cuthbert NJ, Francis DL, Saeed SA. Mechanism of quasi-morphine withdrawal behavior induced by methylxanthines. Eur J Pharmacol 1979; 53(4):375-378.
133. Collier HO, Cuthbert NJ, Francis DL. Character and meaning of quasi-morphine withdrawal phenomena elicited by methylxanthines. Fed Proc 1981; 40(5):1513-1518.
134. Collier HO, Francis DL, Henderson G, Schneider C. Morphine abstinence is associated with increased brain cyclic AMP. Nature 1975; 255(5504):159-162.
135. Collier HO, Francis DL, Henderson G, Schneider C. Quasi morphine-abstinence syndrome. Nature 1974; 249(456):471-473.
136. Salem A, Hope W. Effect of adenosine receptor agonists and antagonists on the expression of opiate withdrawal in rats. Pharmacol Biochem Behav 1997; 57(4):671-679.
137. Zarrindast MR, Naghipour B, Roushan-Zamir F, Shafaghi B. Effects of adenosine receptor agents on the expression of morphine withdrawal in mice. Eur J Pharmacol 1999; 369(1):17-22.
138. Salem A, Hope W. Role of endogenous adenosine in the expression of opiate withdrawal in rats. Eur J Pharmacol 1999; 369(1):39-42.
139. Kaplan GB, Coyle TS. Adenosine kinase inhibitors attenuate opiate withdrawal via adenosine receptor activation. Eur J Pharmacol 1998; 362(1):1-8.
140. Weisberg SP, Kaplan GB. Adenosine receptor antagonists inhibit the development of morphine semitization in the C57BL/6 mouse. Neurosci Lett 1999; 264(1-3):89-92.
141. Coupar IM, Tran BL. Withdrawal and bidirectional cross-withdrawal responses in rats treated with adenosine agonists and morphine. Life Sci 2001; 69(7): 779-790.
142. Wu YN, Mercuri NB, Johnson SW. Presynaptic inhibition of gamma-aminobutyric acid B-mediated synaptic current by adenosine recorded in vitro in midbrain dopamine neurons. J Pharmacol Exp Ther 1995; 273(2):576-581.
143. Avidor-Reiss T, Bayewitch M, Levy R, Matus-Leibovitch N, Nevo I, Vogel Z. Adenylylcyclase supersensitization in mu-opioid receptor-transfected Chinese hamster ovary cells following chronic opioid treatment. J Biol Chem 1995; 270(50):29732-29738.
144. Avidor-Reiss T, Nevo I, Saya D, Bayewitch M, Vogel Z. Opiate-induced adenylyl cyclase superactivation is isozyme-specific. J Biol Chem 1997; 272(8): 5040-5047.
145. Nestler EJ, Tallman JF. Chronic morphine treatment increases cyclic AMP-dependent protein kinase activity in the rat locus coeruleus. Mol Pharmacol 1988; 33(2):127-132.
146. Brundege JM, Williams JT. Increase in adenosine sensitivity in the nucleus accumbens following chronic morphine treatment. J Neurophysiol 2002; 87(3):1369-1375.
147. Kaplan GB, Leite-Morris KA. Up-regulation of adenosine transporter-binding sites in striatum and hypothalamus of opiate tolerant mice. Brain Res 1997; 763(2):215-220.
148. Yao L, Fan P, Jiang Z, Mailliard WS, Gordon AS, Diamond I. Addicting drugs utilize a synergistic molecular mechanism in common requiring adenosine and Gi-βγ dimers. PNAS 2003; 100(24):14379-14384.
149. Sahraei H, Motamedi F, Khoshbaten A, Zarrindast MR. Adenosine A2 receptors inhibit morphine self-administration in rats. Eur J Pharmacol 1999; 383(2):107-113.
150. Calatayud J, Gonzalez A. History of the development and evolution of local anesthesia since the coca leaf. Anesthesiology 2003; 98(6):1503-1508.
151. Everitt BJ, Wolf ME. Psychomotor stimulant addiction: a neural systems perspective. J Neurosci 2002; 22(9):3312-3320.
152. Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, et al. Acute effects of cocaine on human brain activity and emotion. Neuron 1997; 19(3):591-611.
153. Dackis CA, O'Brien CP. Cocaine dependence: a disease of the brain's reward centers. J Subst Abuse Treat 2001; 21(3):111-117.
154. Bonci A, Bernardi G, Grillner P, Mercuri NB. The dopamine-containing neuron: maestro or simple musician in the orchestra of addiction? Trends Pharmacol Sci 2003; 24(4):172-177.
155. Floresco SB, West AR, Ash B, Moore H, Grace AA. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 2003; 6(9):968-973.
156. Grace AA. The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction 2000; 95(Suppl 2):S119-128.
157. Marinelli M, White FJ. Enhanced vulnerability to cocaine self-administration is associated with elevated impulse activity of midbrain dopamine neurons. J Neurosci 2000; 20(23):8876-8885.
158. Volkow ND, Fowler JS, Wang GJ. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J Psychopharmacol 1999; 13(4):337-345.
159. Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 2003; 479:23-40.
160. Chefer VI, Shippenberg TS. Changes in basal and cocaine-evoked extracellular dopamine uptake and release in the rat nucleus accumbens during early abstinence from cocaine: quantitative determination under transient conditions. Neuroscience 2002; 112(4):907-919.
161. Rossetti ZL, Melis F, Carboni S, Gessa GL. Dramatic depletion of mesolimbic extracellular dopamine after withdrawal from morphine, alcohol or cocaine: a common neurochemical substrate for drug dependence. Ann NY Acad Sci 1992; 654:513-516.
162. Self DW, Genova LM, Hope BT, Barnhart WJ, Spencer JJ, Nestler EJ. Involvement of cAMP-dependent protein kinase in the nucleus accumbens in cocaine self-administration and relapse of cocaine-seeking behavior. J Neurosci 1998; 18(5):1848-1859.
163. Carlezon WA Jr, Thome J, Olson VG, Lane-Ladd SB, Brodkin ES, Hiroi N, et al. Regulation of cocaine reward by CREB. Science 1998; 282(5397):2272-2275.
164. Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997; 20(10):482-487.
165. Ferre S, Fuxe K, von Euler G, Johansson B, Fredholm BB. Adenosine-dopamine interactions in the brain. Neuroscience 1992; 51(3):501-512.
166. Mayfield RD, Jones BA, Miller HA, Simosky JK, Larson GA, Zahniser NR. Modulation of endogenous GABA release by an antagonistic adenosine A1/dopamine D1 receptor interaction in rat brain limbic regions but not basal ganglia. Synapse 1999; 33(4):274-281.
167. Solinas M, Ferre S, You Z-B, Karcz-Kubicha M, Popoli P, Goldberg SR. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci 2002; 22(15):6321-6324.
168. 2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci Lett 1996; 212(1):53-56.
169. Harvey J, Lacey MG. A Postsynaptic interaction between dopamine D1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release. J Neurosci 1997; 17(14):5271-5280.
170. 1 receptors form functionally interacting heteromeric complexes. PNAS 2000; 97(15):8606-8611.
171. Agnati LF, Ferre S, Lluis C, Franco R, Fuxe K. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev 2003; 55(3):509-550.
172. 2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 2003; 278(47):46741-46749.
173. 2A adenosine receptors. Neuroscience 2000; 97(1):195-204.
174. Callahan PM, de la Garza R 2nd, Cunningham KA. Mediation of the discriminative stimulus properties of cocaine by mesocorticolimbic dopamine systems. Pharmacol Biochem Behav 1997; 57(3):601-607.
175. Stolerman IP, Samele C, Kamien JB, Mariathasan EA, Hague DS. A bibliography of drug discrimination research, 1992-1994. Behav Pharmacol 1995; 6(7):643-668.
176. Kamien JB, Bickel WK, Hughes JR, Higgins ST, Smith BJ. Drug discrimination by humans compared to nonhumans: current status and future directions. Psychopharmacology (Berl) 1993; 111(3):259-270.
177. Gauvin DV, Criado JR, Moore KR, Holloway FA. Potentiation of cocaine's
178. Harland RD, Gauvin DV, Michaelis RC, Carney JM, Seale TW, Holloway FA. Behavioral interaction between cocaine and caffeine: a drug discrimination analysis in rats. Pharmacol Biochem Behav 1989; 32(4):1017-1023.
179. Garrett BE, Griffiths RR. The role of dopamine in the behavioral effects of caffeine in animals and humans. Pharmacol Biochem Behav 1997; 57(3):533-541.
180. 2A receptors in the adenosinergic modulation of the discriminative-stimulus effects of cocaine and methamphetamine in rats. J Pharmacol Exp Ther 2003; 307(3):977-986.
181. Self DW, Nestler EJ. Relapse to drug-seeking: neural and molecular mechanisms. Drug Alcohol Depend 1998; 51:49-60.
182. Shalev U, Grimm JW, Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev 2002; 54(1):1-42.
183. Schenk S, Partridge B. Cocaine-seeking produced by experimeter- administered drug injections: dose effect relationships in rats. Psychopharmacology (Berl) 1999; 147:285-290.
184. 2-like dopamine receptor agonists. Science 1996; 271(5255):1586-1589.
185. 2-like agonists in rats that self-administer cocaine. J Pharmacol Exp Ther 1999; 291(1):353-360.
186. 2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists. J Pharmacol Exp Ther 2000; 294(2):680-687.
187. Spealman RD, Barrett-Larimore RL, Rowlett JK, Platt DM, Khroyan TV. Pharmacological and environmental determinants of relapse to cocaine-seeking behavior. Pharmacol Biochem Behav 1999; 64(2):327-336.
188. Schenk S, Worley CM, McNamara C, Valadez A. Acute and repeated exposure to caffeine: effects on reinstatement of extinguished cocaine-taking behavior in rats. Psychopharmacology (Berl) 1996; 126(1):17-23.
189. Weerts EM, Griffiths RR. The adenosine receptor antagonist CGS15943 reinstates cocaine-seeking behavior and maintains self-administration in baboons. Psychopharmacology (Berl) 2003; 168(1-2):155-163.
190. 1 receptors, prevents the extinction of cocaine-seeking behavior in mice. J Pharmacol Exp Ther 1999; 290(2):535-542.
191. Green TA, Schenk S. Dopaminergic mechanism for caffeine-produced cocaine seeking in rats. Neuropsychopharmacology 2002; 26(4):422-430.
192. Toda S, McGinty JF, Kalivas PW. Repeated cocaine administration alters the expression of genes in corticolimbic circuitry after a 3-week withdrawal: a DNA macroarray study. J Neurochem 2002; 82(5):1290-1299.
193. 1 receptor in the rat nucleus accumbens. J Neurochem 2003; 87(6):1478-1484.
194. De Witte P, Pinto E, Ansseau M, Verbanck P. Alcohol and withdrawal: from animal research to clinical issues. Neurosci Biobehav Rev 2003; 27(3):189-197.
195. Koob GF. Animal models of craving for ethanol. Addiction 2000; 95(Suppl 2):S73-S81.
196. Spanagel R. Recent animal models of alcoholism. Alcohol Res Health 2000; 24(2):124-131.
197. A receptors in the acute and chronic effects of ethanol. Psychopharmacology (Berl) 1998; 139(1-2):2-19.
198. Melis M, Camarini R, Ungless MA, Bonci A. Long-lasting potentiation of GABAergic synapses in dopamine neurons after a single in vivo ethanol exposure. J Neurosci 2002; 22(6):2074-2082.
199. Siggins GR, Martin G, Roberto M, Nie Z, Madamba S, De Lecea L. Glutamatergic transmission in opiate and alcohol dependence. Ann NY Acad Sci 2003; 1003(1):196-211.
200. Krystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther 2003; 99(1):79-94.
201. Thomas MP, Monaghan DT, Morrisett RA. Evidence for a causative role of N-methyl-D-aspartate receptors in an in vitro model of alcohol withdrawal hyperexcitability. J Pharmacol Exp Ther 1998; 287(1):87-97.
202. Fadda F, Rossetti ZL. Chronic ethanol consumption: from neuroadaptation to neurodegeneration. Prog Neurobiol 1998; 56(4):385-431.
203. Chandler LJ. Ethanol and brain plasticity: receptors and molecular networks of the postsynaptic density as targets of ethanol. Pharmacol Ther 2003; 99(3):311-326.
204. Weiss F, Porrino LJ. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci 2002; 22(9):3332-3337.
205. Brodie MS, McElvain MA, Bunney EB, Appel SB. Pharmacological reduction of small conductance calcium-activated potassium current (SK) potentiates the excitatory effect of ethanol on ventral tegmental area dopamine neurons. J Pharmacol Exp Ther 1999; 290(1):325-333.
206. Brodie MS, Shefner SA, Dunwiddie TV. Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area in vitro. Brain Res 1990; 508(1):65-69.
207. 2 receptor-deficient mice. Pharmacol Biochem Behav 2000; 67(4):693-699.
208. 2 receptors. Nat Neurosci 1998; 1(7):610-615.
209. Dar MS, Mustafa SJ, Wooles WR. Possible role of adenosine in the CNS effects of ethanol. Life Sci 1983; 33(14):1363-1374.
210. Proctor WR, Dunwiddie TV. Behavioral sensitivity to purinergic drugs parallels ethanol sensitivity in selectively bred mice. Science 1984; 224(4648):519-521.
211. Nagy L, Diamond I, Casso D, Franklin C, Gordon A. Ethanol increases extracellular adenosine by inhibiting adenosine uptake via the nucleoside transporter. J Biol Chem 1990; 265(4):1946-1951.
212. Krauss SW, Ghirnikar RB, Diamond I, Gordon AS. Inhibition of adenosine uptake by ethanol is specific for one class of nucleotide transporters. Mol Pharmacol 1993; 44(5):1021-1026.
213. Mailliard WS, Diamond I. Recent advances in the neurobiology of alcoholism: the role of adenosine. Pharmacol Ther 2004; 101:39-46.
214. Kovacs GL, Toldy E. Basal and isoproterenol-stimulated cyclic-adenosine monophosphate levels in mouse hippocampus and lymphocytes during alcohol tolerance and withdrawal. Alcohol Alcohol 2003; 38(1):11-17.
215. Dohrman DP, Diamond I, Gordon AS. Ethanol causes translocation of cAMP-dependent protein kinase catalytic subunit to the nucleus. PNAS 1996; 93(19):10217-10221.
216. Mochly-Rosen D, Chang FH, Cheever L, Kim M, Diamond I, Gordon AS. Chronic ethanol causes heterologous desensitization of receptors by reducing as messenger RNA. Nature 1988; 333(6176):848-850.
217. Wand G, Diehl A, Levine M, Wolfgang D, Samy S. Chronic ethanol treatment increases expression of inhibitory G-proteins and reduces adenylylcyclase activity in the central nervous system of two lines of ethanol-sensitive mice. J Biol Chem 1993; 268(4):2595-2601.
218. Coe IR, Dohrman DP, Constantinescu A, Diamond I, Gordon AS. Activation of cyclic AMP-dependent protein kinase reverses tolerance of a nucleotide transporter to ethanol. J Pharmacol Exp Ther 1996; 276(2).
219. 2A receptors in the alcohol withdrawal syndrome. Alcohol 1999; 19(2):157-162.
220. 2A, receptor density in mouse brain. Brain Res 1998; 786(1-2):80-88.
221. 2A receptors. J Neurosci 2002; 22(23):10487-10493.
222. Gatch MB, Selvig M. Theophylline blocks ethanol withdrawal-induced hyperalgesia. Alcohol Alcohol 2002; 37(4):313-317.
223. 2A adenosine receptor knockout mice. J Neurochem 2004; 88(4):827-834.
224. Schiffmann SN, Dassesse D, d'Alcantara P, Ledent C, Swillens S, Zoli M. A2A receptor and striatal cellular functions: regulation of gene expression, currents, and synaptic transmission. Neurology 2003; 61(11 Suppl 6):S24-29.
225. Barwick VS, Dar MS. Adenosinergic modulation of ethanol-induced motor incoordination in the rat motor cortex. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22(4):587-607.
226. 1 adenosinergic receptor. Brain Res Bull 2001; 55(4):513-520.
227. Meng ZH, Pennington SN, Dar MS. Rat striatal adenosinergic modulation of ethanol-induced motor impairment: possible role of striatal cyclic AMP. Neuroscience 1998; 85(3):919-930.
228. 1 adenosine receptor antisense in mice. Brain Res 2002; 957(1):53-60.
229. Nyce JW. Insight into adenosine receptor function using antisense and geneknockout approaches. Trends Pharmacol Sci 1999; 20:79-83.
230. 1 receptor antisense oligodeoxynucleotide blocks ethanol-induced motor incoordination. Eur J Pharmacol 1997; 323(2-3):R5-R7.
231. 1 receptor antisense infused in striatum of rats: actions on alcohol-induced locomotor impairment, blood alcohol, and body temperature. Alcohol 1997; 14(6):617-621.
232. 2A receptor or its chronic blockade decrease ethanol withdrawal-induced seizures in mice. Neuropharmacology 2001; 40(3):424-432.
233. 2A receptors. Trends Pharmacol Sci 1996; 17(10):364-372.
234. Gatch MB, Wallis CJ, Lal H. The effects of adenosine ligands R-PIA and CPT on ethanol withdrawal. Alcohol 1999; 19(1):9-14.
235. Imaizumi M, Miyazaki S, Onodera K. Effects of xanthine derivatives in a light/dark test in mice and the contribution of adenosine receptors. Methods Find Exp Clin Pharmacol 1994; 16(9):639-644.
236. Jain N, Kemp N, Adeyemo O, Buchanan P, Stone TW. Anxiolytic activity of adenosine receptor activation in mice. Br J Pharmacol 1995; 116(3):2127-2133.
237. Gatch MB, Lal H. Effects of ethanol and ethanol withdrawal on nociception in rats. Alcohol Clin Exp Res 1999; 23(2):328-333.
238. Daly JW, Fredholm BB. Caffeine-an atypical drug of dependence. Drug Alcohol Depend 1998; 51:199-206.
239. Jacobsen K, von Lubitz DK, Daly JW, Fredholm BB. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci 1996; 17:108-113.
240. Daly JW. Mechanism of action of caffeine. In: Garattini S, editor. Caffeine, Coffee and Health. New York: Raven Press, 1993.
241. 1 receptors. J Pharmacol Exp Ther 1995; 273(2):637-642.
242. Morton RA, Davies CH. Regulation of muscarinic acetylcholine receptor-mediated synaptic responses by adenosine receptors in the rat hippocampus. J Physiol 1997; 502(Pt 1):75-90.
243. Brockwell NT, Eikelboom R, Beninger RJ. Caffeine-induced place and taste conditioning: production of dose-dependent preference and aversion. Pharmacol Biochem Behav 1991; 38(3):513-517.
244. 2 adenosine receptor subtypes in locomotor activity and place conditioning in rats. Behav Pharmacol 1996; 7(4):373-383.
245. 2A receptors. Br J Pharmacol 2000; 129(7):1465-1473.
246. Holtzman SG, Mante S, Minneman KP. Role of adenosine receptors in caffeine tolerance. J Pharmacol Exp Ther 1991; 256(1):62-68.
247. Nehlig A. Are we dependent upon coffee and caffeine? A review on human and animal data. Neurosci Biobehav Rev 1999; 23:563-576.
248. Svenningsson P, Nomikos GG, Fredholm BB. The stimulatory action and the development of tolerance to caffeine is associated with alterations in gene expression in specific brain regions. J Neurosci 1999; 19(10):4011-4022.
249. Evans SM, Griffiths RR. Caffeine withdrawal: a parametric analysis of caffeine dosing conditions. J Pharmacol Exp Ther 1999; 289(1):285-294.
250. 1 adenosine receptor binding. J Pharmacol Exp Ther 1993; 266(3):1563-1572.
251. Campbell FA, Tramer MR, Carroll D, Reynolds DJM, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323(7303):13.
252. 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001; 92:91-100.
253. Iversen L, Chapman V. Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol 2002; 2(1):50-55.
254. Vaughan CW, Christie MJ. An analgesic role for cannabinoids. Med J Aust 2000; 173(5):270-272.
255. Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 1998; 38(1):179-200.
256. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54(2):161-202.
257. 2receptors. Pharmacol Ther 1997; 74(2):129-180.
258. Iversen L. Cannabis and the brain. Brain 2003; 126(6):1252-1270.
259. 1. J Comp Neurol 2000; 422(2):159-171.
260. Vaughan CW, Connor M, Bagley EE, Christie MJ. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 2000; 57(2):288-295.
261. Vaughan CW, McGregor IS, Christie MJ. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br J Pharmacol 1999; 127(4):935-940.
262. Levenes C, Daniel H, Soubrie P, Crepel F. Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J Physiol (Lond) 1998; 510(3):867-879.
263. Huang C-C, Chen Y-L, Lo S-W, Hsu K-S. Activation of cAMP-dependent protein kinase suppresses the presynaptic cannabinoid inhibition of glutamatergic transmission at corticostriatal synapses. Mol Pharmacol 2002; 61(3):578-585.
264. Huang C-C, Lo S-W, Hsu K-S. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol (Lond) 2001; 532(3):731-748.
265. Hajos N, Katona I, Naiem SS, Mackie K, Ledent C, Mody I, et al. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 2000; 12(9):3239-3249.
266. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 1999; 19(11):4544-4558.
267. Hajos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 2001; 106(1):1-4.
268. 1 receptors by cannabinoids. Eur J Neurosci 1998; 10(9):2825-2830.
269. Melis M, Gessa GL, Diana M. Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24(6):993-1006.
270. Maldonado R, Rodriguez de Fonseca F. Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 2002; 22(9):3326-3331.
271. Tanda G, Goldberg SR. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms-a review of recent preclinical data. Psychopharmacology (Berl) 2003; 169(2):115-134.
272. 9-tetrahydrocannabinol in mice. Drug Alcohol Depend 2000; 60:113-119.
273. Rubino T, Vigano D, Massi P, Parolaro D. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940. J Neurochem 2000; 75(5):2080-2086.
274. Smith NT. A review of the published literature into cannabis withdrawal symptoms in human users. Addiction 2002; 97(6):621-632.
275. 9-tetrahydrocannabinol. Br J Pharmacol 1998; 125(7):1567-1577.
276. 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 1996; 278(3):1290-1295.
277. 9- tetrahydrocannabinol. J Pharmacol Exp Ther 1998; 285(3):1150-1156.
278. 1 receptor in the mouse. Brain Res 2000; 864:186-194.
279. 1 receptor in cannabinoid-induced motor incoordination in the acute and tolerant state in mice. Brain Res 2001; 905:178-187.
280. Craig ADB. Pain mechanisms: labeled lines versus convergence in central processing. Annu Rev Neurosci 2003; 26(1):1-30.
281. Ren K, Dubner R. Descending modulation in persistent pain: an update. Pain 2002; 100(1-2):1-6.
282. Millan MJ. Descending control of pain. Progr Neurobiol 2002; 66(6):355-474.
283. Sawynok J. Adenosine receptor activation and nociception. Eur J Pharmacol 1998; 317:1-11.
284. Sjolund K-F, Segerdahl M, Sollevi A. Adenosine reduces secondary hyperalgesia in two human models of cutaneous inflammatory pain. Anesth Analg 1999; 88(3):605.
285. Post C. Antinociceptive effects in mice after intrathecal injection of 5′-N-ethylcarboxamide adenosine. Neurosci Lett 1984; 51(3):325-330.
286. 1 receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 2002; 125(6):1392-1401.
287. 1 adenosine receptor. Pain 2001; 94:315-324.
288. 2 receptors of the substantia gelatinosa are located predominantly on intrinsic neurons: an autoradiography study. J Pharmacol Exp Ther 1988; 247(2):757-764.
289. McQuay HJ. Neuropathic pain: evidence matters. Eur J Pain 2002; 6(Suppl A):11-18.
290. Sawynok J, Esser MJ, Reid AR. Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. J Psychiatry Neurosci 2001; 26(1):21-29.
291. Esser MJ, Chase T, Allen GV, Sawynok J. Chronic administration of amitriptyline and caffeine in a rat model of neuropathic pain: multiple interactions. Eur J Pharmacol 2001; 430:211-218.
292. Esser MJ, Sawynok J. Caffeine blockade of the thermal antihyperalgesic effect of acute amitryptyline in a rat model of neuropathic pain. Eur J Pharmacol 2000; 399:131-139.
293. Ulugol A, Karadag HC, Tamer M, Firat Z, Aslantas A, Dokmeci I. Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats. Neurosci Lett 2002; 328(2):129-132.
294. Sawynok J, Reid AR, Esser MJ. Peripheral antinociceptive action of amitriptyline in the rat formalin test: involvement of adenosine. Pain 1999; 80(1-2):45-55.
295. Phillis JW, Wu PH. The effect of various centrally active drugs on adenosine uptake by the central nervous system. Comp Biochem Physiol 1982; 72:179-187.
296. Sweeney MI, White TD, Sawynok J. Morphine-evoked release of adenosine from the spinal cord occurs via a nucleoside carrier with differential sensitivity to dipyridamole and nitrobenzylthioinosine. Brain Res 1993; 614(1-2):301-307.
297. Sander-Kiesling A, Li X, Eisenach JC. Morphine-induced spinal release of adenosine is reduced in neuropathic rats. Anesthesiology 2001; 95:1455-1459.
298. 2A receptor gene. J Neurosci 2002; 22(21):9210-9220.
299. Rane K, Segerdahl M, Goiny M, Sollevi A. Intrathecal adenosine administration: a phase 1 clinical safety study in healthy volunteers, with additional evaluation of its influence on sensory thresholds and experimental pain. Anesthesiology 1998; 89(5):1108-15; discussion 9A.
300. Eisenach JC, Hood DD, Curry R. Phase I safety assessment of intrathecal injection of an American formulation of adenosine in humans. Anesthesiology 2002; 96(1):24-28.
301. Poon A, Sawynok J. Antinociceptive and anti-inflammatory properties of an adenosine kinase inhibitor and an adenosine deaminase inhibitor. Eur J Pharmacol 1999; 384:123-138.
302. Pan H-L, Xu Z, Leung E, Eisenach JC. Allosteric adenosine modulation to reduce allodynia. Anesthesiology 2001; 95:416-420.
303. Li X, Conklin D, Pan H-L, Eisenach JC. Allosteric adenosine receptor modulation reduces hypersensitivity following peripheral inflammation by a central mechanism. J Pharmacol Exp Ther 2003; 305(3):950-955.
304. 3 adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (mGluR) function and uncouple mGluRs from GTP-binding proteins. J Neurosci 1998; 18(16):6138-6146.
305. 1 receptor-mediated responses in rat hippocampus. J Neurosci 1997; 17(2):607-614.
306. Manzoni OJ, Williams JT. Presynaptic regulation of glutamate release in the ventral tegmental area during morphine withdrawal. J Neurosci 1999; 19(15):6629-6636.
307. 1 of the rat hippocampus. Neurosci Lett 1991; 122(1):50-52.